» Articles » PMID: 34830703

Changes in Treatment Patterns and Globe Salvage Rate of Advanced Retinoblastoma in Korea: Efficacy of Intra-Arterial Chemotherapy

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Nov 27
PMID 34830703
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: To analyze changes in treatment patterns for advanced retinoblastoma over time and differences in globe salvage rates; (2) Methods: Retrospective, observational case-control study of 97 eyes of 91 patients with advanced retinoblastoma (Group D and E).; (3) Results: Patients were divided into two groups based on whether they were treated before or after intraarterial chemotherapy (IAC) was introduced in our center in 2010. Before 2010, primary treatment pattern was enucleation, which was performed in 57.6% of cases, whereas primary treatment pattern after 2010 was IAC combined with intravenous chemotherapy (IVC), which was performed in 78.1%. Intravitreal chemotherapy (IVitC) has been performed to treat vitreous and subretinal seeding since 2015. The 5-year globe salvage rate of IVC alone was 24.0% for Group D and 0% for Group E, whereas that of IVC-IAC was 50.4% for Group D and 49.7% for Group E. Whether IVitC was performed or not did not significantly contribute to globe salvage rate. There was one metastatic death in the IVC alone group.; (4) Conclusions: Primary treatment pattern changed from enucleation to IAC-based treatment, which can now save nearly half of eyes with advanced retinoblastoma with excellent safety profile and survival rate.

Citing Articles

Intra-arterial chemotherapy in refractory and advanced intraocular retinoblastoma.

Kumari N, Jain N, Saboo S, Parthasarathy R, Gupta V, Mahajan A Indian J Ophthalmol. 2023; 71(2):436-443.

PMID: 36727336 PMC: 10228906. DOI: 10.4103/ijo.IJO_1388_22.


Spotlight on Targeted Chemotherapy in Retinoblastoma: Safety, Efficacy, and Patient Outcomes.

Naseripour M, Mirshahi R, Kasraei H, Sedaghat A, Azimi F Onco Targets Ther. 2022; 15:1545-1561.

PMID: 36579184 PMC: 9792108. DOI: 10.2147/OTT.S370878.


Intra-arterial chemotherapy for retinoblastoma: Our first experience in Indonesia.

Sidipratomo P, Pandelaki J, Matondang S, Ramandika H, Sitorus R, Karismaputri K Radiol Case Rep. 2022; 17(12):4713-4716.

PMID: 36199445 PMC: 9527629. DOI: 10.1016/j.radcr.2022.09.004.


The Efficacy of Alternate Systemic Intravenous Chemotherapy and Intra-arterial Chemotherapy Approach for Eye Globe Salvage in Retinoblastoma.

Han J, Lee C, Hahn S, Ahn W, Kim H, Yun H Cancer Res Treat. 2022; 55(1):270-278.

PMID: 35609621 PMC: 9873333. DOI: 10.4143/crt.2021.1537.

References
1.
Abramson D, Schefler A . Update on retinoblastoma. Retina. 2004; 24(6):828-48. DOI: 10.1097/00006982-200412000-00002. View

2.
Shields C, Mashayekhi A, Au A, Czyz C, Leahey A, Meadows A . The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006; 113(12):2276-80. DOI: 10.1016/j.ophtha.2006.06.018. View

3.
Hahn S, Kim H, Kim D, Lee S, Lyu C, Han J . Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma. Pediatr Hematol Oncol. 2016; 33(1):74-82. DOI: 10.3109/08880018.2015.1135363. View

4.
Chen M, Zhao J, Xia J, Liu Z, Jiang H, Shen G . Intra-Arterial Chemotherapy as Primary Therapy for Retinoblastoma in Infants Less than 3 Months of Age: A Series of 10 Case-Studies. PLoS One. 2016; 11(8):e0160873. PMC: 4978489. DOI: 10.1371/journal.pone.0160873. View

5.
Shields C, Fulco E, Arias J, Alarcon C, Pellegrini M, Rishi P . Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond). 2012; 27(2):253-64. PMC: 3574237. DOI: 10.1038/eye.2012.175. View